Li Guiping, Wang Yongxian, Huang Kai, Zhang Hui, Peng Wuhe, Zhang Chunfu
Radiopharmaceutical Research Centre, Shanghai Institute of Applied Physics, the Chinese Academy of Sciences, Shanghai, 201800, P.R. China.
Nucl Med Biol. 2005 Jan;32(1):59-65. doi: 10.1016/j.nucmedbio.2004.09.003.
The therapeutic efficacy of radioimmunotherapy (RIT) of 188Re-labeled herceptin, which is a humanized anti-p185-HER2/neu monoclonal antibody (mAb), was studied. The nude mice bearing nasopharyngeal carcinoma (NPC) expressing HER2/neu protooncogene were injected with 188Re-herceptin intratumorally and intravenously. The biodistribution was observed on day 2 (n = 3). The tumor growth inhibition rate (IR) was determined by measurement of tumor volume. In the intratumorally treated mice, tumor uptake of 188Re-herceptin was significantly greater than in the intravenously treated mice [11.53% injected dose (ID)/g vs. 2.79% ID/g at 48 h], and lower normal organ uptake was also seen. The intratumoral administration of 188Re-herceptin caused greater inhibition of tumor growth at the fourth week as compared to the intravenous administration. It is concluded that intratumoral administration of 188Re-herceptin makes high level of radioactivity retained in tumor with significantly lower radioactivity retained in normal tissues, and provides a more effective regional therapy for NPC overexpressing HER2/neu.
研究了188Re标记的赫赛汀（一种人源化抗p185-HER2/neu单克隆抗体）的放射免疫疗法（RIT）的治疗效果。对表达HER2/neu原癌基因的鼻咽癌（NPC）裸鼠进行瘤内和静脉注射188Re-赫赛汀。在第2天观察生物分布（n = 3）。通过测量肿瘤体积确定肿瘤生长抑制率（IR）。在瘤内治疗的小鼠中，188Re-赫赛汀的肿瘤摄取明显高于静脉治疗的小鼠[48小时时为11.53%注射剂量（ID）/克 vs. 2.79% ID/克]，且正常器官摄取也较低。与静脉给药相比，瘤内给予188Re-赫赛汀在第四周对肿瘤生长的抑制作用更大。结论是，瘤内给予188Re-赫赛汀可使肿瘤中保留高水平的放射性，而正常组织中保留的放射性明显较低，并为过表达HER2/neu的NPC提供更有效的局部治疗。
Nan Fang Yi Ke Da Xue Xue Bao. 2006-4
RSC Med Chem. 2022-1-14
Front Med (Lausanne). 2019-6-14
Zotero 插件